Agoracom Blog Home

Posts Tagged ‘CSE’

Empower Clinics $CBDT.ca Expands COVID-19 Testing Programs by Commencing RT-PCR Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:56 AM on Thursday, September 10th, 2020
  • Commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower
  • programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

VANCOUVER BC / September 10, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower.

The programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

RT-PCR Testing can be booked via: https://www.sunvalleyhealth.com/covid-19-test-book-now/

Currently Kai Medical Laboratory has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine.

“Launching our RT-PCR testing programs utilizing the capability of Kai Medical Labs gives us the ability to access massive testing volume not only in Arizona, but nationwide in the U.S.” said Steven McAuley, Empower’s Chairman & CEO. “Our team at Sun Valley Health has created numerous strategic marketing campaigns to drive awareness and testing volume, leveraging our supply chain improvements with increased profit margins.”

Many schools and universities are now requiring students and teachers to provide RT-PCR testing results prior to returning to campus. Our nasal or throat swab RT-PCR testing program allow students and teachers to quickly be tested and receive results from a Clinical Laboratory Improvement Amendments (CLIA), accredited laboratory in only 24 – 48 hours.

Businesses need a stable workforce, and must be quick to isolate employees with any symptoms. Our RT-PCR testing allows employees to be tested quickly and receive results within 24 – 48 hours, giving the employee and the employer the opportunity to activate non-contagious employees and safely return to work!

Travelers are also discovering demands to get a RT-PCR test and provide the result upon check-in at the airport. The reports are required to be no more than 3 days old. Our testing program provides accurate results within 24-48 hours, giving the patient a document that can make the difference in being able to travel.

https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-testing.html
https://www.wsj.com/articles/universities-plan-robust-covid-19-testing-for-returning-students-11594812937

An RT-PCR assay is a viral molecular test to detect active infection directly in a patient’s RNA genetic sequence. An RT-PCR swab test is considered the gold-standard for testing & diagnosing active viral infections and should be used for anyone who has symptoms or known exposure to COVID-19. These tests are renowned for high sensitivity and high specificity.

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

USA COVID-19 Data as at September 9, 2020
TOTAL CASES: 6,310,663
TOTAL DEATHS: 189,147
CASES IN LAST 7 DAYS: 262,971

ARIZONA as at September 9, 2020
CONFIRMED CASES: 204,239
PROBABLE CASES: 1,806
TOTAL CASES: 206,045
CASES IN LAST 7 DAYS: 3,703
CASES/100K: 2,873
DEATHS/100K: 72

TEXAS as at September 9, 2020
TOTAL CASES: 641,791
CASES IN LAST 7 DAYS: 24,458
CASES/100K: 2,236
DEATHS/100K: 47

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

$HPQ.ca Silicon Confirms Closing of $2.7M Private Placement at 50% Premium to Market $DUK $XEL $NEE $PYR.ca

Posted by AGORACOM-JC at 2:46 PM on Wednesday, September 9th, 2020
  • On target to produce strongly sought-after nano silicon powders and nanowires for delivery and testing to battery industry parties in December
  • Company also confirms the September 3, 2020 closing of the $2,700,000 at $0.60, non-brokered private placement, announced on September 1, 2020
  • Now well funded to push forward on our nano silicon initiatives for the battery sector and others renewable energy applications, from which HPQ has currently announced two (2) NDA’s (Non-Disclosure Agreements)

MONTREAL, Sept. 09, 2020 — HPQ Silicon Resources Inc. (“HPQ” or “the Company”) TSX-V: HPQ; FWB: UGEOther OTC : URAGF; is issuing this press release in response to recent market activity.  HPQ does not usually comment on stock price and trading activity, however, given recent activity and inquiries from investors, the Company would like to confirm that everything material about the Company’s operations has been disclosed and that HPQ is on target to produce our strongly sought-after nano silicon powders and nanowires for delivery and testing to battery industry parties in December.

The Company also confirms the September 3, 2020 closing of the $2,700,000 at $0.60, non-brokered private placement, announced on September 1, 2020.  As a result of this financing, HPQ has never been as well funded to push forward on our nano silicon initiatives for the battery sector and others renewable energy applications, from which HPQ has currently announced two (2) NDA’s (Non-Disclosure Agreements).

“HPQ PUREVAPTM Quartz Reduction Reactor (QRR) and HPQ NANO PUREVAPTM Nano Silicon Reactor (NSiR) processes are unique processes that will allow us to deliver to advanced materials companies and battery manufacturers a cost competitive, tailor-made product, that can replace graphite in batteries and thereby allow the deployment of truly powerful next generation Li-ion batteries,” said Bernard Tourillon, President & CEO of HPQ Silicon.  “These processes open up unique multibillion-dollar business opportunity for HPQ and PyroGenesis, as we strive to deliver the critical Silicon nano-materials required by the surging Li-ion battery market and other large renewable energy markets.”

INTEREST IN PUREVAPTM NSiR GAME CHANGING LOW COST POTENTIAL

Research indicates that replacing graphite with Nano Silicon (Si) Powders could allow the manufacturing of high-performance Li-ion batteries to deliver an almost tenfold (10x) increase in anode capacity, inducing a 20-40% gain in the energy density of the next generation of Li-Ion batteries. Silicon Nanomaterial potential to meet energy storage demand of the future is undeniable and is generating massive investments.

Despite the strong research and investment in Silicon nanomaterial, current manufacturing processes to make Nano Silicon powders are not scalable or commercially viable. By December of this year, HPQ will be on the starting blocks of demonstrating a process that can address both the scalability and cost hurdles required by the industry. 

About Silicon

Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) presently under way.  Silicon does not exist in its pure state; it must be extracted from quartz (SiO2), in what has historically been a capital and energy intensive process.

About HPQ Silicon

HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal,  building a portfolio of unique high value specialty silicon products needed for the coming RER.

Working with PyroGenesis Canada Inc. (TSX-V: PYR), a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:

  • The PUREVAPTM “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential;
         
    º  HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
  • The PUREVAPTM Nano Silicon Reactor (NSiR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires;
         º  HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries;
       
      º  During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAPTM SiNR.

HPQ is also working with industry leader Apollon Solar of France to:

  • Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders;
         º  The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries.
         º  The plan is to deliver porous Si wafer to a battery manufacturer (under NDA) for testing in 2020.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders. 

Disclaimers:

The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected]

EVENT: You’re invited to Datametrex $DM.ca Investor Webinar on September 15th @ 1 PM EST.

Posted by AGORACOM-JC at 1:18 PM on Wednesday, September 9th, 2020
Webinar logo

You’re invited to our Investor Webinar on September 15th @ 1 PM EST. We will be discussing the Q2 financials, and the following topics: COVID-19 Testing and AI technology.

Please click the link below to register: 

https://us02web.zoom.us/webinar/register/WN_FZc3a5nlQiKlsTEq5bqFfQ

FansUnite $FANS.ca B2C Platform Continues Strong Performance as Sport Returns $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 9:26 AM on Wednesday, September 9th, 2020

McBookie Ltd sees Increase of 412% Year-over-Year on Gross Gaming Revenue

  • Scottish based operator increased its overall year-over-year turnover for the months of July and August by 108% – from $3M CAD to $6.3M CAD, with 78% of the turnover growth led by the return of sport
  • Increase resulted in a YOY increase in Gross Gaming Revenue over the same period of 412%, resulting in gross gaming revenue of $371K for July and August 2020 and a gross margin of $161K
  • During the same period last year the platform generated $72K in gross gaming revenue resulting in a gross margin loss of $66K

Vancouver, British Columbia and Dundee, Scotland–(September 9, 2020) – FansUnite Entertainment Inc. (CSE: FANS) (OTC Pink: FUNFF), (“FansUnite” or the “Company”), a technology company providing leading online gaming solutions is pleased to announce McBookie Ltd (“McBookie”) has continued its impressive performance since becoming part of FansUnite.

The Scottish based operator increased its overall year-over-year (“YOY”) turnover for the months of July and August by 108% – from $3M CAD to $6.3M CAD, with 78% of the turnover growth led by the return of sport.

The increase resulted in a YOY increase in Gross Gaming Revenue over the same period of 412%, resulting in gross gaming revenue of $371K for July and August 2020 and a gross margin of $161K. During the same period last year the platform generated $72K in gross gaming revenue resulting in a gross margin loss of $66K.

With the strong results over the last two months, McBookie is preparing to continue the positive trend with the return of the English Premier League and the other major European leagues in the coming weeks.

“We are very pleased that McBookie has been able to continue its strong 2020 performance despite the slowdown in sports betting from the global pandemic,” said Scott Burton, CEO of FansUnite. “The figures for the past 60 days have been exceptional and continue to validate our belief in this leading B2C betting brand and the management team behind it. For the duration of 2020, major European leagues are set to begin again and present a great opportunity for McBookie to capture the attention of new and existing customers. We will work directly with McBookie in ensuring their presence in the U.K. expands and they are in a position to service this growing user base of bettors.”

“The team at FansUnite has worked very hard to improve all aspects of our business since joining FansUnite and it is great to see that replicated in the numbers,” said Paul Petrie, founder and Director of McBookie. “With just one month to wait until the whole of Scottish football is back, having the resources and expertise of FansUnite helps puts us in an excellent position to continue building on our recent success.”

While the return of sport has provided an uptick in betting volume, casino turnover during the two-month period was strong as well with $3.1M wagered. McBookie will be looking to build on these numbers with the recent launch of a Live Casino product earlier this month.

“After launching a successful Virtual Sports betting offering in March, we decided to expand our platform with the addition of a Live Casino,” continued Paul Petrie. “It represents another betting alternative for our loyal customers and helps us diversify our revenue stream.”

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
[email protected]
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
[email protected]

Darius Eghdami President of FansUnite
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: the leveraging of GameCo’s US license infrastructure; GameCo becoming an official reseller of the platform; the Company’s entrance into the US market and the Company’s strategy with respect thereto; the importance of the US market to the Company; impacts of the GameCo/Askott partnership on the Company’s success; the Company’s ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

MedX Health Corp. $MDX.ca Announces Management Changes and Increased Focus on SIAscopy™ on DermSecure™ $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 8:20 AM on Wednesday, September 9th, 2020
Home - MedX Health
  • Completed management changes to enhance its focus on its dermatological services and products including DermSecure™ and SIAscopy™
  • Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products.

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™.

Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products. The supporting teams in sales, training, production as well as software and hardware development for DSP will report to Mr. Druhan. “Mike and his team will continue to build out the Brazilian, Canadian and Dutch markets where we have established sales but more importantly, this refocus will allow more resources to be devoted to our initiatives in the United States, Latin America and Europe,” said Rob von der Porten, Executive Chair and interim CEO.

“I have full confidence in the capability of my team and the outstanding strengths of our technologies, SIAscopy™ and DermSecure™, which together form, in our view, the leading teledermatological offering in the world,” noted Mike Druhan. “As we have already seen, it saves lives and has a huge potential that we are starting to exploit. Consequently, we are relaunching the MedX website in the coming week, with much improved content on our dermatological focus, in keeping with our driving strategy,” he continued.

Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director Light Therapy Products, with responsibility over sales of these products in Canada and the United States. He will work with our Canadian and US-based sales and distributor network.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality light therapy products, including therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Rob von der Porten
MedX Health Corp
[email protected]

Hilaria Baldwin Joins Else Nutrition $BABY.ca as a Brand Ambassador for Plant-Based Toddler Nutrition Launch in U.S. $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:16 AM on Wednesday, September 9th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin
  • Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition

VANCOUVER, BC / September 9, 2020 / Else Nutrition Holdings (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company”), is pleased to announce its partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin. Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition.

As a mom who has always advocated a plant-based lifestyle, the collaboration originated from Hilaria’s own search for a suitable toddler formula alternative for her children. Baldwin will help Else through creative social media and video content that highlights her findings and journey as a plant-based mother.

“Hilaria embodies our brand values through her desire to take baby nutrition to the next level with a heightened awareness for health and wellness,” said Mrs. Hamutal Yitzhak, CEO and Co-Founder of Else. “She is a true champion of the cause, which makes us beyond excited about this collaboration. Together, we hope to raise awareness of the benefits of clean-label, plant-based baby nutrition for this generation and the future ones to come.”

“I am thrilled to be partnering with Else Nutrition. As many of you know, my family primarily eats a dairy-free, plant-based diet. I nurse my babies and am always looking for a plant-based toddler formula to transition to once they are weaned. There hasn’t been anything suitable except soy until now. Else is complete, whole Nutrition and my toddler Romeo genuinely loves it. It’s really the alternative that I had been looking for, and I believe that so many other parents like myself have been longing for it as well,” said Mrs. Hilaria Baldwin.

Most recently, Else made its debut on national U.S. television. Baldwin appeared on E!’s popular midday show, Daily Popwhere she explained why Else is her choice for her toddler, Romeo. Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is available for order on Else’s e-store at elsenutrition.com.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QB board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

About Hilaria Baldwin

Hilaria Baldwin (@hilariabaldwin) is the Co-Host of Mom Brain, Apple’s #1 parenting podcast; the author of The Living Clearly Method: 5 Principles for a Fit Body, Healthy Mind & Joyful Life (Rodale; December 2016); and Co-Founder of Yoga Vida in NYC. She is also a monthly contributor to TODAY.com’s One Small Thing platform and to People’s People Parents Squad. Hilaria lives in NYC with her husband Alec and their four children, Carmen Gabriella, Rafael Thomas, Leonardo Angel and Romeo Alejandro David, and they’re currently expecting their fifth child.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For additional information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the Company’s anticipated partnership with Mrs. Baldwin. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others Forward-looking statements made in this press release assume, among others, the successful partnership between the Company and Mrs. Baldwin. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

ImagineAR $IP.ca $IPNFF Signs Five Year $250,000 USD Licensing Agreement with WaV Sports & Entertainment $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:12 AM on Wednesday, September 9th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Contract Revenue is $250,000 USD Plus 5 Year Joint Partnership Program Revenue Fees
  • Licensing agreement to provide its Augmented Reality Platform to WaV Sports & Entertainment for the launch of their new proprietary line of global sports engagement products
  • In addition to the five-year licensing fee, the agreement also provides for joint revenue sharing fees over the term which can significantly increase the annual revenue for ImagineAR

VANCOUVER, BC and ERIE, Pa., Sept. 9, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) is excited to announce the signing of a five year $250,000USD licensing agreement to provide its Augmented Reality Platform to WaV Sports & Entertainment for the launch of their new proprietary line of global sports engagement products. In addition to the five-year licensing fee, the agreement also provides for joint revenue sharing fees over the term which can significantly increase the annual revenue for ImagineAR.

Brian Klaasmeyer, Co-Founder & Managing Partner of WaV Sports & Entertainment stated “Our partnership with ImagineARTM is going to address the new paradigm required today in professional sports for fan engagement and activation.  The ImagineAR augmented reality platform is truly a gamechanger for sports organizations and athletes to deliver in-home mobile phone engagement and drive consistent recurring monthly revenue for them. We are extremely optimistic that with our experienced executive team, we will generate significant revenue for our clients for years.”

Dean Dalton, Co-Found & Managing Partner of WaV Sports & Entertainment, and former NFL Minnesota Vikings Coach added “We have been analyzing new technologies and platforms for revolutionizing sports and fan engagement. Augmented Reality has been one of our keystone requirements and the ImagineAR platform is years ahead of every other company today.” 

Alen Paul Silverrstieen, CEO of ImagineAR, stated “Our new advisor, Gus Frerotte, introduced the founders of WaV Sports and Entertainment to ImagineAR as he realized the potential of a partnership for both organizations.  We believe the WaV Sports fan engagement business model and current relationships are going to be a catalyst for driving significant revenue for ImagineAR in 2020 and for the duration of the five-year agreement.” 

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

ABOUT WaV Sports & Entertainment

WaV Sports & WaV Sports & Entertainment is a global sports marketing firm that specializes in sports property representation, brand side representation, and the management and production of unique sporting and entertainment events.  WaV exclusively represents the NFL Alumni Academy and various other NFL Alumni projects such as their youth educational programming known as Pro Day Experience.  WaV Sports & Entertainment has partnered with ImagineAR to expand their reach into the world of sports. Additional information on the Company can be found at www.WaVsports.com

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables sports organizations and businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

For more information or to explore working with Imagination Park, please email [email protected], or visit www.imagineAR.com.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagination Park Entertainment Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by Imagination Park’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

July #Cannabis Sales Surge in 5 Western States – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:08 PM on Tuesday, September 8th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 230 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. Revenue generated for the three-month period ended June 30th, 2020 was USD $8.47 million. Learn More

July Cannabis Sales Surge in 5 Western States

  • In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019.
  • Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
A Detailed Look at Cannabis Sales in California, Oregon, Arizona, Colorado and Nevada

Data provided by BDSA indicates that cannabis sales continued their robust expansion in 5 Western states. During July, the eleventh month after the onset of the vaping crisis and the fifth month of the pandemic impacting the market, sales across the five markets totaled $842.8 million, up 12% from June, which sequential increases of 2% in May and 14% in April. March had spiked to $666.0 million from $579.9 million in February as customers purchased cannabis ahead of store closures and concerns about limitations on access, so clearly cannabis sales are back on track. With the near-term effects of the pandemic now behind us, it’s clear that cannabis demand is surging, even in relatively mature markets, like Oregon and Colorado. Nevada continued to recover as tourism slowly returns, with sales growing 23%. California stood out with 15% sequential growth, while Colorado expanded 13%. Oregon sales climbed 6% and Arizona by 3%, but both of these states had meteoric growth from a year ago. July had one more day than June, which has the effect of adding 3% roughly.

Overall sales growth from a year ago among the five Western markets ranged from 26% in California to as high as 54% in Arizona. Nevada has been impacted by the tourist slowdown but still grew 37% from a year ago. Oregon continued its strong growth, rising 44%, while Colorado grew 35%. Concentrates represented 22-37% of sales by market, below the 26-38% share of sales last August before the vaping crisis hit.

Here is a closer look at each market, as detailed by BDSA:

Arizona

In July 2020, cannabis sales in Arizona’s medical dispensaries reached $94.2 million, growing three percent from June and over 54 percent compared to the previous July. Year-to-date through July, sales have reached $589.2 million, increasing by $194.5 million and 49 percent compared to the same period last year.

Flower sales accounted for nearly 48 percent of overall revenue for the month with $44.8 million in sales, growing one percent from June. Pre-rolled Joints, which are tracked as a separate category, accounted for just under four percent of revenue with $3.5 million in sales. Compared to the previous July, Flower sales increased by 52 percent and Pre-rolled Joints increased by 83 percent.

Concentrate sales accounted for about 37 percent of overall revenues with sales totaling $34.6 million in July, increasing six percent from the trailing month. Vape products, the largest segment of the Concentrates category, generated $21.8 million in sales, accounting for 63 percent of the Arizona Concentrates market and over 23 percent of sales across all categories. Compared to July 2019, sales of Dabbable Concentrates grew by 92 percent, while Vape sales grew by 46 percent.

The Ingestibles category accounted for nearly 11 percent of sales in July with $10 million in revenue for the month. Compared to July 2019 and June 2020, sales in the category grew by 47 percent and by four percent, respectively. In July, the $9.3 million in sales from Edibles generated nearly 93 percent of Ingestibles sales overall, while Sublinguals made up the remaining seven percent. Compared to the previous July, Edibles sales increased by 59 percent and Sublingual sales decreased by 30 percent.

California

BDSA sales reporting for the month of July reflects the state market of 699 licensed dispensary locations and 306 delivery operators.

In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019. Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.

Sales from Flower generated $136.2 million in July 2020, accounting for nearly 41 percent of overall revenues. Compared to the trailing month and July 2019, Flower sales grew by 17 percent and 53 percent, respectively. Pre-rolled Joints, which are tracked as a separate category, accounted for nearly 11 percent of overall July revenues, with $35.6 million in sales.

Concentrates were the second-largest revenue category in July 2020, reaching $101 million in sales and accounting for over 30 percent of total revenue. Compared to the trailing month and July 2019, sales increased by 13 percent and by four percent, respectively. The $76 million in Vape sales accounted for over 75 percent of the Concentrates category and 23 percent of the month’s overall sales revenue.

In July 2020, Ingestibles generated $50.8 million in sales, increasing by 11 percent from the trailing month. Compared to July 2019, sales of Ingestibles grew by nearly 21 percent. Edibles contributed 86 percent of Ingestibles revenue, while Sublinguals made up the remaining 14 percent. Compared to July 2019, the Edibles and Sublinguals categories grew by 32 percent and declined by 22 percent, respectively.

Colorado

July 2020 was another milestone for the Colorado cannabis market. Sales in Colorado’s adult-use and medical dispensaries reached a combined $226.8 million, growing 13 percent from June. Compared to the previous July, sales increased by nearly 35 percent. Adult-use sales grew by 33 percent from July 2019 while medical sales grew by 41 percent. Year-to-date through July, combined channel sales have reached over $1.2 billion, increasing 22 percent from the same period last year.

In July, Flower sales accounted for over 47 percent of total monthly revenues, totaling at $107.2 million. Flower sales increased nearly 11 percent from the trailing month and grew 56 percent from the previous July. Year-to-date sales have increased by 40 percent in the category over the same period last year. Pre-rolled Joints, which are tracked separately from Flower, generated $13.2 million in sales for July 2020, growing 31 percent from July 2019 and increasing 17 percent from the trailing month.

The $66.5 million in Concentrate sales during July 2020 represented an 18 percent increase from the previous year and 15 percent growth from the trailing month. The category accounted for over 29 percent of revenue for the month. Vape products, the largest segment within the Concentrates category, reached $32.9 million in July sales, increasing 19 percent compared to June and four percent from the previous July, respectively. The Vape category accounted almost 50 percent of Concentrates’ revenue and 15 percent of overall sales for the month.

In July 2020, sales from Ingestibles generated $34.7 million, a 27 percent increase from July 2019. Compared to the trailing month, sales in the category grew by 17 percent. Edibles generated $32.7 million in monthly sales revenue, contributing over 94 percent to category sales and 14 percent of total revenue for the month. Sublinguals made up the remaining six percent of Ingestibles sales, totaling $1.9 million for the month.

Nevada

In July, Nevada dispensaries generated $82 million in sales. Compared to July of 2019, sales grew by 37 percent and by nearly 23 percent compared to the trailing month. Year-to-date through July, sales have reached $421.9 million, growing by six percent compared to the same period last year.

Flower sales accounted for nearly 54 percent of overall July 2020 sales. Sales in the category reached $44.1 million for the month, growing 27 percent from June. Pre-rolled Joints, tracked separately from Flower, accounted for nearly 11 percent of July sales, with $8.8 million in revenue. Compared to July 2019, Flower and Pre-rolled Joints sales have increased by 75 percent and by two percent, respectively.

Concentrate sales in July reached $18.3 million, accounting for more than 22 percent of overall revenue for the month. Compared to the trailing month as well as to the previous July, category sales increased by 17 percent. Vape products, the largest segment in the Concentrates category, generated $13.3 million for the month, contributing nearly 73 percent to Concentrates revenue and over 16 percent to total monthly sales.

Sales in the Ingestibles category accounted for 11 percent of all revenues, totaling $9.1 million in July sales and growing by about seven percent from the previous year. Compared to June, category sales grew by 17 percent. Edibles made up 90 percent of the Ingestibles category, reaching $8.2 million in July revenue, and Sublingual sales contributed the remaining ten percent.

Oregon

In July 2020, cannabis sales in Oregon’s medical and adult-use dispensaries reached a combined $106 million. Compared to the trailing month, sales in the Oregon market grew by about six percent, while compared to July 2019, sales grew by 45 percent overall. Year-to-date sales in Oregon have reached $620.3 million, growing by 39 percent compared to the same period in 2019.

Sales of Flower generated $50.3 million in July 2020, accounting for 47 percent of overall revenues. Compared to the trailing month, Flower sales grew by four percent, and compared to July 2019, sales increased by 65 percent. Pre-rolled Joints, which are tracked as a separate category, accounted for nine percent of overall revenues with $9.8 million in sales.

Concentrates generated $27.7 million in July sales. Compared to the trailing month and July 2019, sales in the category increased five percent and just over 25 percent, respectively. Vape products, the largest segment in the Concentrates category, generated $15 million in July, contributing over 54 percent of Concentrates sales and more than 14 percent of total monthly revenue.

In July 2020, Ingestibles generated over $14.6 million in sales, a nine percent increase from the previous month and nearly 25 percent compared to July 2019. Edibles, which made up 83 percent of the Ingestibles category and more than 11 percent of overall monthly sales, generated $12 million in July 2020.

For readers looking for a deeper look at cannabis markets across these five states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how the BDSA GreenEdge Platform can provide you with unlimited access to the most accurate and actionable data and analysis.

Source: https://www.newcannabisventures.com/july-cannabis-sales-surge-in-5-western-states/

Avicanna $AVCN.ca August 2020 Recap $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 12:04 PM on Tuesday, September 8th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

AVICANNA AUGUST 2020 RECAP

Achievements and Announcements 
August has been another incredibly progressive month for the Avicanna team with major commercial milestones being achieved. This included the nation-wide launch of our leading medical cannabis brand RHO Phyto in partnership with Medical Cannabis by Shoppers Drug Mart in Canada, the closing of a private placement financing, export of rare cannabinoids including CBG into the Unites States and strategic partnership with Red White and Bloom to distribute Pura H&W in the United States. 

See below highlights and press releases:
 
August 24, 2020

Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany as well as Industrial Scale THC Quota Granted by the Colombian Authorities

Avicanna majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“) completed exports of CBG and CBD isolates into the United States, CBD isolate into Germany and the commencement of a pilot tracking system for the export of its active pharmaceutical ingredient (“API“) products in partnership with TruTrace Technologies Inc. (“TruTrace“) (CSE: TTT) (OTCQB: TTTSF). The export and sale of the commercial lot of isolated CBG into the United States was completed in parallel with commercial export of isolated CBD into the United States, as well as a pilot export for R&D purposes of CBD into Germany.  The Colombian Ministry of Justice and Law granted SMGH a supplementary cultivation quota to cultivate 12,264 psychoactive cannabis plants. 11,587 plants will be destined to produce dry flower which will then be used to manufacture psychoactive derivatives for commercial production for export. The remaining 677 plants will be utilized for psychoactive derivatives for the purposes of research and development and pilot production of our RHO Phyto™ branded products in Colombia.
 
News Release
 
August 18, 2020

Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million

Avicanna closed a non-brokered private placement (the “Offering“). Under the Offering, Avicanna issued an aggregate of 1,952,410 units (the “Units“) at a price of CAD$1.40 per Unit for aggregate gross proceeds of approximately CAD$2.7 million. Avicanna intends to use the proceeds from the Offering for corporate development and general working capital purposes.
News Release
 
August 17, 2020
 
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Successfully launched advanced “medical cannabis 2.0” products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart Revenue increase of 172% from $260,903 in Q1 2020 to $709,468 in Q2 2020, and a substantial increase from $16,571 in Q2 2019, coupled with 8% cost reduction from Q1 2020, and 31% cost reduction from Q2 2019 Continued to fortify cannabinoid research and clinical leadership position in Canada with advancements with several collaborations with world class institutions including the MC-RWE by UHN
News Release
 
August 12, 2020

Avicanna’s RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical Cannabis by Shoppers Inc.

RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners on the Medical Cannabis by Shoppers™ platform. This product line includes advanced formulations under the “Cannabis 2.0” regulations that have undergone years of research and development and been manufactured under GMP standards at MediPharm Labs Inc. The RHO Phyto products are also now available to clinicians and patients at the University Health Network through the Medical Cannabis Real World Evidence study in partnership with Medical Cannabis by Shoppers.
News Release
 
August 11, 2020

Avicanna and Red White & Bloom enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived CBD-Based Topical Products in the United States

Avicanna entered into a distribution agreement for the exclusive distribution of our advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by Red White Bloom (“RWB”) in the US and certain other markets. The launch of this innovative and premium hemp-derived CBD product line will leverage from the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform, third party e-commerce channels, and “big box” retailers in addition to the existing commercial infrastructure of RWB in the United States.
News Release
 
IN CASE YOU MISSED THIS
 
August 7, 2020

Avicanna Inc. to Host Second Quarter 2020 Investor Conference Call Avicanna announced its first ever second quarter 2020 investor conference call on August 17, 2020. 

Q2 2020 Earnings Call Transcript

InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, September 8th, 2020
Innocan-Blog

Iris Bincovich, CEO of InnoCan Pharma Corp, shares with Cannabis Report World an overview on how they are disrupting the cannabis world through pharmaceutical innovation and gives us a preview of some of their latest projects one of which is targeting the COVID-19 virus.

Can you introduce us to InnoCan? Where did the idea for the concept originate from?

InnoCan Pharma Corporation is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals.

The founders and officers of InnoCan, all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

InnoCan Pharma was established by Yoram Drucker, an Israeli serial entrepreneur with experience of founding companies in the field of stem cells; Ron Mayron Former CEO of Teva Israel. Teva Pharmaceutical is one of the largest generic drug producers in the world; Nir Avram, our topicals formulator, who was on the pharmaceutical innovation team at Perrigo, he holds a number of patents and has more than 30 years of experience developing topicals; and I bringing a world-wide experience in healthcare with nearly 20 years of international marketing, business development and sales experience. I have led and managed hundreds of successful international transactions in the OTC, cosmetics and dermatology sector.

InnoCan was established as a Pharma company, to enhance the therapeutic properties of CBD, developing unique synergistic delivery systems and OTC/cosmetic products.

Some of our latest projects and products: InnoCan with the Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both Central Nervous System (CNS) indications and the Covid-19 Corona Virus using CBD-loaded Exosomes.

CBD-loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

In addition, InnoCan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection.

Together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, we plan to test the liposome platform on several potential indications.

InnoCan Pharma also develops and manufactures OTC products: R&G Relief & Go – a breakthrough patent-pending CBD pain relief brand, integrating CBD with other pharmaceutical ingredients.

InnoCan’s Pain relief spray provides fast action muscle relaxant and pain relief. It contains an analgesic blend of active ingredients with pure CBD to provide temporary relief of muscle and joint pain.

We also developed a line of Premium derma cosmetic CBD-integrated anti-aging product lines: SHIR, where its formulations feature a tailored blend of active ingredients and technology.

Can you tell us more about your innovative products?

1) Our latest project is a collaboration targeting the COVID-19 virus with Tel Aviv University and Professor Daniel Offen, who heads The Laboratory for Neurosciences at the Felsenstein Medical Research Center.

We are developing an inhalable treatment based on exosomes loaded with CBD, designed to target COVID-19 infected lung cells and might be applicable also to central nervous system diseases.

Exosomes have the ability to target damaged cells like a targeted missile, they improve regeneration and assist in their recovery. CBD is a known anti-inflammatory substance.

Exosomes have been studied for their cell recovery actions and inflammation targeting.  CBD-loaded exosomes (“CLX”) may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. The CBD loaded exosomes are expected to be administered by inhalation.

Together with Professor Offen, an experienced researcher on cell and gene therapy in neurodegenerative diseases, we are looking to develop a new technology that might be applicable to several indications. Prof. Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics (traded on NASDQ, symbol BCLI), developed cell treatment for ALS patients, and is now in Phase III clinical trial.

2) In addition, we are advancing a platform for injectable CBD loaded liposomes in collaboration with Prof. Barenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem. This accurate, controlled administration of CBD by injection, is expected to be as easy as injecting insulin.

Upon every administration of CBD Oil, about 80% of the CBD is being throwed of by enzymes in the liver.  CBD Oil is not easily absorbed, only 5-10 % is ultimately being absorbed.  Patients may be overloaded to achieve a therapeutic level.

CBD is an oily molecule that normally cannot be easily injected into the body.  But once isolated inside a capsule, such as a Liposome, it could be injected.  Liposomes are small vesicles, that could entrap substance inside. The Liposomes technology is planned to enable increase bioavailability and control dosage and provide controlled release of CBD over time.

We are developing a platform for several potential indications.

For example, for people who are suffering from chronic pain, we may be able to offer an injection once a week, and over time, one could have a consistent release of CBD into the body.

Professor Barenholz has already developed a Liposome based breast cancer drug, named Doxil, that was licensed by Johnson & Johnson based on royalties from revenues.

InnoCan Pharma is collaborating with leading researchers’ leader in their fields.

This is one of few value-driven propositions of the company.

3) Innocan Pharma™ leverages extensive knowledge and understanding of the synergistic combination of CBD and FDA-Approved active ingredients for fast-acting relief of severe and acute pain.

R&G is a fast action muscle relaxant and pain relief brand and contains an analgesic blend of active ingredients with CBD. The brand provides temporary relief of muscle and joint pain.

These are EU-GMP manufactured products, clinically tested for safety

This PATENT PENDING UNIQUE FORMULATION combines the known benefits of CBD, Magnesium, Camphor and Menthol to relieve pain, help relax and recover after performing like professionals.

Combining these 4 ingredients at high concentrations, and developing a stable product is highly challenging.  So how does it work? Here is some science:

  • CBD- CBD is a potent antioxidant with anti-inflammatory properties. CBD is known to have a positive effect on pain and reduce swelling.
  • Menthol–a topical analgesic (pain reliever). Menthol produces a cooling sensation by stimulating the skin’s thermos-receptors, which send the brain a signal that is interpreted as cold, numbing effect.
  • Magnesiumchloride – is a known muscle relaxant and food supplement. We developed it into an easy-to-absorb form that may be able to raise levels of this nutrient within the body when applied topically to the skin.
    • The magnesium, absorbed through the skin, is claimed to relieve muscle pains and aches and to enhance relaxation.
  • Camphor- Assists to relieve pain and swelling and inflammation, and preventing skin redness.

4) Dermo cosmetic products powered by science, inspired by nature. SHIR, our beauty & science skincare brand combines the benefits of CBD with the most effective ingredients in innovative formulas to deliver visible fast acting results.

InnoCan Pharma has developed several premium lines of derma cosmetic products containing a tailor blend of highly concentrated ingredients, formulated with CBD. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.

Can you describe the consumer’s behaviour towards cannabis – integrated pharmaceuticals?

As far as we know consumers are waiting to integrate Innocan Pharma’s innovation into their routine.

What challenges have you faced so far in the cannabis market and how were these overcome?

InnoCan Pharma disrupts the Cannabis world. As a pharmaceutical company, we do not grow nor extract, we focus on research and development of drug delivery platforms combining pure cannabidiol with Synergistics delivery systems of ingredients. Our challenge was to distinguish ourselves as a pharma company with highest quality standards to provide consumer confidence.

What so you see happening over the next few years regarding pharma products? What is your general prediction for the sector?

As a pharmaceutical company we predict that the Cannabis industry will move towards a much more regulated industry. Our prediction is that we will see more companies offering variety of products that combine cannabinoids among their ingredients.

What are the plans for the future and your ultimate goal?

To become a Global Leader in Cannabinoid-Integrated Pharmaceutical Products and to Improve the quality of life.

Source: https://cannabisreportworld.com/innocan-developing-revolutionary-products-that-harness-the-unique-properties-of-cannabinoids-combined-with-smart-delivery-formulations/